AceView offers a comprehensive annotation of human, mouse and nematode genes
reconstructed by co-alignment and clustering of all publicly available
mRNAs and ESTs on the genome sequence. Our goals are to offer a reliable
up-to-date resource on the genes, their functions, alternative variants,
expression, regulation and interactions, in the hope to stimulate
further validating experiments at the bench
This site normally requires a frame enabled viewer,
However, click here to access our full description of gene CCDC91.
, go to our main page or see our latest news
Homo sapiens complex locus CCDC91, encoding protein CRA c family member.
TABLE OF CONTENTS / OPEN CLOSE ALL PARAGRAPHS
Compact gene diagram
Alternative mRNAs are shown aligned from 5' to 3' on a virtual genome where introns have been shrunk to a minimal length. Exon size is proportional to length, intron height reflects the number of cDNAs supporting each intron. Introns of the same color are identical, of different colors are different. 'Good proteins' are pink, partial or not-good proteins are yellow, uORFs are green. 5' cap or3' poly A flags show completeness of the transcript.
Read more...
Mouse over the ending of each transcript gives tissues from which the supporting cDNAs were extracted. Details on tissue of origin for each intron and exon is available from the
intron and exons table.
Click on any transcript to open the specific mRNA page, to see the exact cDNA clone support and eventual SNPs and to get details on tissues, sequences, mRNA and protein annotations. Proteins supported by a single continuous cDNA sequence lead to underlining the name/ending of the variant. Names not underlined result from cDNA concatenation in the coding region and should be experimentally checked.
Introns are depicted by broken lines; the height of the top of each intron reflects the relative number of clones supporting this intron.
]^[ A pink broken line denotes an intron with standard boundaries (gt-ag or gc-ag) that is exactly supported (i.e. a cDNA sequence exactly matches the genome over 16 bp, 8 on both sides of the intron).
] ^ ] A blue broken line denotes non-standard introns, exactly supported, but with non-standard at-ac or any other boundaries.
]-[ Pink and
] - ] blue straight lines represent 'fuzzy' introns of the standard and non-standard types respectively, those introns do not follow the 16 bp rule. Black straight lines ]-[denote gaps in the alignments.
Exons: Wide filled pink areas represent putative protein coding regions, narrow empty pink boxes represent the 5'UTR (on the left) and 3' UTR (on the right). Flags identify validated endings: cap site on the 5' side, polyadenylation site on the 3' side. Filled flags correspond to frequent events while empty flags have lesser supporting cDNAs (yet all are validated); at the 3' side, black flags are associated to the main AATAAA signal,
blue flags to any single letter variant of the main . More explanations are given in the
gene help file
Expression and GenBank cDNA support
Tissues where expression was observed (from 239 cDNA clones)
Origin of the cDNAs, as reported in GenBank/dbEST (tissue, stage, pathological or normal) shows that the gene is expressed in testis (seen 26 times), bladder (11), lung (11), carcinoma, cell line (10), brain (9), germinal center B cell (9), breast carcinoma (8), placenta (8), prostate (7), eye (5), head neck (5), kidney (5), placenta cot 25-normalized (5), skin (5), thalamus (5), adenocarcinoma (4), breast (4), liver (4), amygdala (3), colon (3), 2 pooled tumors (clear cell type) (2), breast normal (2), embryonal carcinoma (2), fetal eyes, lens, eye anterior segment,optic nerve, retina, retina foveal and macular, RPE andchoroid (2), hepatoblastoma (2), hypothalamus (2), lymph (2), nervous normal (2), ovary (2), pooled germ cell tumors (2), stomach (2), substantia nigra (2), t-lymphocytes (2), three pooled meningiomas (2), trachea (2), two pooled squamous cell carcinomas (2), uterus (2), whole embryo, mainly body (2), adrenal gland (once), alveolar macrophage (once), aorta (once), blastocyst (once), carcinoid (once), cervix (once), cochlea (once), colon tumor RER+ (once), colonic mucosa from 5 ulcerative colitispatients (once), cornea (once), duodenal adenocarcinoma, cell line (once), ear (once), embryonic stem cells, dmso-treated H9 cellline (once), epidermis (once), epithelioid carcinoma (once), fetal eye (once), fibrosarcoma (once), fibrotheoma (once), frontal lobe (see description) (once), heart (once), hippocampus (once), kidney, tumor tissue (once), large cell carcinoma, undifferentiated (once), leiomyosarcoma (once), liver, tumor tissue (once), lymph node (once), lymphoma, follicular mixed small and largecell (once), malignant melanoma, metastatic to lymphnode (once), mammary adenocarcinoma, cell line (once), medulla (once), melanotic melanoma (once), muscle (skeletal) (once), nervous tumor (once), nose (once), olfactory epithelium (once), optic nerve (once), ovary (pool of 3) (once), ovary, tumor tissue (once), pancreas (once), pituitary (once), placenta normal (once), pluripotent cell line derived fromblastocyst inner cell mass (once), pooled human melanocyte, fetal heart, andpregnant uterus (once), poorly differentiated adenocarcinoma withsignet ring cell features (once), primitive neuroectoderm (once), sciatic nerve (once), small intestine (once), spleen (once), squamous cell carcinoma (once), squamous cell carcinoma, poorlydifferentiated (4 pooled tumors, including primary andmetastatic) (once), uterus tumor (once), whole brain (once).
239 cDNA clones support the 29 variants of gene CCDC91
?
This table helps analyze the pattern of expression of the gene, the tissue, cell type or disease state specificity of the alternative variants and to select cDNA clones suitable for your experiments.
cDNA accession Links to the sequence |
Tissue
most 5' clones in red |
Match mRNA |
From bp to bp in mRNA |
From bp to bp in accs. |
Clone encodes complete protein (with AA variation) |
Features |
Anomalies detected by AceView |
Accession match over (% length) |
Base differences relative to genome (% identity) |
DA303929 | hippocampus | CCDC91.a | 1 to 557 | 2 to 560 | | tiling clone, capped | | 559/559 (100 %) | 4 diff (99.3 %id) |
DA947779 | Spleen | CCDC91.a | 17 to 580 | 2 to 568 | | capped | | 567/567 (100 %) | 4 diff (99.3 %id) |
DA692611 | | CCDC91.a | 30 to 589 | 2 to 567 | | capped | | 566/566 (100 %) | 7 diff (98.8 %id) |
DA696788 | | CCDC91.a | 30 to 601 | 2 to 573 | | capped | | 572/572 (100 %) | 1 diff (99.9 %id) |
DA833382 | placenta | CCDC91.a | 30 to 653 | 2 to 626 | | capped | | 625/625 (100 %) | 3 diff (99.6 %id) |
DA390133 | thalamus | CCDC91.a | 36 to 605 | 2 to 571 | | capped | | 570/570 (100 %) | 2 diff (99.7 %id) |
DA168991 | amygdala | CCDC91.a | 41 to 614 | 2 to 576 | | capped | | 575/575 (100 %) | 2 diff (99.7 %id) |
DA874859 | Prostate | CCDC91.a | 48 to 596 | 2 to 550 | | capped | | 549/549 (100 %) | 1 diff (99.9 %id) |
AV751617 | Pituitary | CCDC91.a | 69 to 667 | 1 to 598 | | | | 598/785 (76 %) | 16 diff (98.0 %id) |
DN991116 | brain, whole brain | CCDC91.a | 81 to 734 | 1 to 653 | | | | 653/653 (100 %) | 7 diff (99.0 %id) |
DA815341 | | CCDC91.a | 123 to 680 | 2 to 559 | | tiling clone, capped | | 558/558 (100 %) | 1 diff (99.9 %id) |
AW407227 | lymph | CCDC91.a | 153 to 538 | 1 to 386 | | | Possibly primed on the genome, locally A rich (19/20 A in genome downstream of last aligned base) | 386/386 (100 %) | 7 diff (98.2 %id) |
TI_154145153 | | CCDC91.a | 159 to 700 | 79 to 619 | | | | 541/626 (86 %) | 20 diff (96.9 %id) |
DA715361 | | CCDC91.a | 171 to 693 | 2 to 526 | | capped | | 525/525 (100 %) | 3 diff (99.5 %id) |
AY289196 | | CCDC91.a | 213 to 1562 | 1 to 1350 | A36T V314M | tiling clone, | | 1350/1350 (100 %) | 2 diff (99.9 %id) |
NM_018318.3 | | CCDC91.a | 213 to 2546 | 1 to 2334 | exact | RefSeq, AAA | Possibly primed on the genome, locally A rich (19/20 A in genome downstream of last aligned base) | 2334/2334 (100 %) | 0 diff (100 %id) |
DA473587 | | CCDC91.a | 318 to 879 | 2 to 563 | | capped | | 562/562 (100 %) | 0 diff (100 %id) |
AK001950 | placenta | CCDC91.a | 727 to 2546 | 1 to 1820 | | tiling clone, available from FLJ, | | 1820/1820 (100 %) | 1 diff (100.0 %id) |
AU136903 | placenta | CCDC91.a | 728 to 1443 | 2 to 719 | | capped | | 718/839 (85 %) | 4 diff (99.6 %id) |
AA447947 | | CCDC91.a | 774 to 1274 | 1 to 500 | | | | 500/501 (99 %) | 3 diff (99.5 %id) |
AY251168 | testis | CCDC91.a | 830 to 1583 | 1 to 754 | | | | 754/754 (100 %) | 0 diff (100 %id) |
CR457277 | | CCDC91.a | 832 to 1554 | 1 to 723 | | | | 723/723 (100 %) | 3 diff (99.6 %id) |
BX390351 | Placenta Cot 25-normalized | CCDC91.a | 946 to 1905 | 1 to 960 | | | | 960/960 (100 %) | 38 diff (96.1 %id) |
BM550955 | duodenal adenocarcinoma, cell line, small intestine | CCDC91.a | 987 to 1863 | 8 to 896 | | | | 889/1099 (80 %) | 27 diff (97.6 %id) |
BG194469 | | CCDC91.a | 989 to 1555 | 584 to 17 | | | Submitted on the opposite strand | 568/857 (66 %) | 16 diff (98.2 %id) |
BX371573 | Placenta Cot 25-normalized | CCDC91.a | 989 to 1711 | 730 to 9 | | | | 722/836 (86 %) | 5 diff (99.5 %id) |
BP290625 | lung | CCDC91.a | 1040 to 1613 | 1 to 574 | | | | 574/574 (100 %) | 1 diff (99.9 %id) |
AI125366 | | CCDC91.a | 1077 to 1573 | 499 to 3 | | | | 497/499 (99 %) | 1 diff (99.8 %id) |
AW117294 | pooled | CCDC91.a | 1124 to 1629 | 512 to 7 | | | | 506/512 (98 %) | 1 diff (99.9 %id) |
AI025289 | | CCDC91.a | 1133 to 1573 | 443 to 3 | | | | 441/443 (99 %) | 0 diff (100 %id) |
AI187421 | | CCDC91.a | 1133 to 1573 | 444 to 4 | | | | 441/444 (99 %) | 1 diff (99.8 %id) |
BX095287 | | CCDC91.a | 1159 to 1572 | 1 to 414 | | AAA | Possibly primed on the genome, locally A rich (19/20 A in genome downstream of last aligned base) | 414/414 (100 %) | 1 diff (99.8 %id) |
AI371837 | pooled germ cell tumors | CCDC91.a | 1174 to 1572 | 399 to 1 | | | | 399/399 (100 %) | 1 diff (99.8 %id) |
BM717356 | eye, fetal eyes, lens, eye anterior segment,optic nerve, retina, Retina Foveal and Macular, RPE andChoroid | CCDC91.a | 1177 to 1751 | 1 to 575 | | | Possibly primed on the genome, locally A rich (19/20 A in genome downstream of last aligned base) | 575/575 (100 %) | 1 diff (99.9 %id) |
BE876582 | large cell carcinoma, undifferentiated, lung | CCDC91.a | 1191 to 1831 | 1 to 650 | | | | 650/662 (98 %) | 24 diff (96.4 %id) |
AA621335 | | CCDC91.a | 1193 to 1573 | 382 to 2 | | | | 381/382 (99 %) | 1 diff (99.8 %id) |
AA634293 | | CCDC91.a | 1204 to 1629 | 427 to 2 | | | | 426/427 (99 %) | 0 diff (100 %id) |
BQ217754 | epithelioid carcinoma, Pancreas | CCDC91.a | 1212 to 1626 | 455 to 41 | | AAA | Submitted on the opposite strand | 415/896 (46 %) | 1 diff (99.9 %id) |
BF102514 | adenocarcinoma, Prostate | CCDC91.a | 1214 to 1886 | 1 to 668 | | | | 668/853 (78 %) | 23 diff (97.4 %id) |
BF102743 | adenocarcinoma, Prostate | CCDC91.a | 1214 to 1881 | 1 to 665 | | | | 665/1157 (57 %) | 35 diff (97.0 %id) |
BF102724 | adenocarcinoma, Prostate | CCDC91.a | 1214 to 1851 | 1 to 630 | | AAA | | 630/840 (75 %) | 23 diff (97.3 %id) |
DB507812 | testis | CCDC91.a | 1216 to 1626 | 1 to 411 | | AAA | Submitted on the opposite strand | 411/411 (100 %) | 2 diff (99.6 %id) |
DB526212 | testis | CCDC91.a | 1219 to 1626 | 1 to 408 | | AAA | Submitted on the opposite strand | 408/408 (100 %) | 0 diff (100 %id) |
AU120242 | whole embryo, mainly body | CCDC91.a | 1223 to 2045 | 2 to 822 | | fully sequenced, capped | | 821/821 (100 %) | 3 diff (99.7 %id) |
BG682293 | skin, squamous cell carcinoma | CCDC91.a | 1264 to 1974 | 1 to 712 | | | | 712/712 (100 %) | 3 diff (99.6 %id) |
DB515822 | testis | CCDC91.a | 1296 to 1626 | 78 to 408 | | | Submitted on the opposite strand | 331/408 (81 %) | 7 diff (98.3 %id) |
BG199005 | | CCDC91.a | 1327 to 2099 | 1 to 773 | | | | 773/774 (99 %) | 5 diff (99.4 %id) |
BE925911 | breast_normal | CCDC91.a | 1351 to 1596 | 249 to 1 | | | | 247/249 (99 %) | 7 diff (97.2 %id) |
BF697975 | brain, primitive neuroectoderm | CCDC91.a | 1351 to 2000 | 1 to 646 | | | | 646/896 (72 %) | 28 diff (96.9 %id) |
BG743337 | skin | CCDC91.a | 1365 to 2166 | 1 to 798 | | | | 798/798 (100 %) | 4 diff (99.5 %id) |
BG505979 | embryonal carcinoma, testis | CCDC91.a | 1397 to 2040 | 1 to 643 | | | | 643/644 (99 %) | 8 diff (98.8 %id) |
BF059215 | pooled germ cell tumors | CCDC91.a | 1399 to 1626 | 241 to 14 | | AAA | Possibly primed on the genome, locally A rich (19/20 A in genome downstream of last aligned base) | 228/228 (100 %) | 3 diff (98.7 %id) |
AA889709 | | CCDC91.a | 1425 to 1626 | 223 to 22 | | AAA | Possibly primed on the genome, locally A rich (19/20 A in genome downstream of last aligned base) | 202/203 (99 %) | 0 diff (100 %id) |
AA215390 | germinal center B cell | CCDC91.a | 1429 to 1587 | 1 to 159 | | | | 159/159 (100 %) | 0 diff (100 %id) |
AI431278 | aorta | CCDC91.a | 1438 to 1564 | 129 to 3 | | | | 127/131 (96 %) | 0 diff (100 %id) |
BG204181 | | CCDC91.a | 1441 to 1626 | 1 to 185 | | AAA | Possibly primed on the genome, locally A rich (19/20 A in genome downstream of last aligned base) | 185/185 (100 %) | 9 diff (95.2 %id) |
BG193486 | | CCDC91.a | 1450 to 2119 | 67 to 732 | | | | 666/825 (80 %) | 61 diff (92.7 %id) |
BG204182 | | CCDC91.a | 1451 to 2234 | 1 to 784 | | | | 784/785 (99 %) | 17 diff (97.9 %id) |
R88037 | brain | CCDC91.a | 1459 to 1840 | 1 to 391 | | | | 391/428 (91 %) | 15 diff (96.5 %id) |
BG217895 | | CCDC91.a | 1463 to 1627 | 1 to 167 | | | | 167/168 (99 %) | 5 diff (97.1 %id) |
BF207609 | bladder, carcinoma, cell line | CCDC91.a | 1483 to 2081 | 1 to 595 | | | | 595/596 (99 %) | 9 diff (98.5 %id) |
BU739164 | eye, fetal eyes, lens, eye anterior segment,optic nerve, retina, Retina Foveal and Macular, RPE andChoroid | CCDC91.a | 1884 to 2546 | 681 to 19 | | tiling clone, AAA | Possibly primed on the genome, locally A rich (19/20 A in genome downstream of last aligned base) | 663/663 (100 %) | 1 diff (99.9 %id) |
AW575490 | lymph | CCDC91.a | 1962 to 2546 | 602 to 18 | | AAA | Possibly primed on the genome, locally A rich (19/20 A in genome downstream of last aligned base) | 585/585 (100 %) | 0 diff (100 %id) |
AU156923 | placenta | CCDC91.a | 1998 to 2546 | 556 to 1 | | | | 556/559 (99 %) | 14 diff (97.5 %id) |
AU146363 | whole embryo, mainly body | CCDC91.a | 2024 to 2546 | 522 to 1 | | fully sequenced, | | 522/522 (100 %) | 13 diff (97.6 %id) |
DB380087 | placenta | CCDC91.a | 2085 to 2546 | 461 to 1 | | | | 461/556 (82 %) | 5 diff (99.2 %id) |
AA448881 | | CCDC91.a | 2141 to 2546 | 406 to 1 | | | | 406/406 (100 %) | 1 diff (99.8 %id) |
AA215501 | germinal center B cell | CCDC91.a | 2144 to 2487 | 344 to 1 | | | | 344/345 (99 %) | 2 diff (99.5 %id) |
CN289860 | embryonic stem cells, DMSO-treated H9 cellline | CCDC91.b | 1 to 702 | 1 to 701 | | tiling clone, | | 701/701 (100 %) | 2 diff (99.8 %id) |
BC018679 | lung | CCDC91.b | 58 to 1570 | 1 to 1513 | | tiling clone, available from MGC, AAA | | 1513/1517 (99 %) | 3 diff (99.9 %id) |
BG534885 | lung | CCDC91.b | 61 to 712 | 1 to 660 | | available from MGC, | | 660/660 (100 %) | 40 diff (94.0 %id) |
CR980323 | T-Lymphocytes | CCDC91.b | 1374 to 2009 | 1 to 636 | | tiling clone, | | 636/636 (100 %) | 1 diff (99.9 %id) |
BJ991296 | hepatoblastoma | CCDC91.c | 1 to 578 | 8 to 585 | | tiling clone, | | 585/585 (100 %) | 1 diff (99.9 %id) |
DB192483 | ovary, tumor tissue | CCDC91.c | 4 to 562 | 2 to 560 | | capped | | 559/559 (100 %) | 2 diff (99.7 %id) |
DB205258 | trachea | CCDC91.c | 12 to 603 | 2 to 599 | | capped | | 598/598 (100 %) | 6 diff (99.0 %id) |
CR740655 | pooled | CCDC91.c | 114 to 310 | 1 to 197 | | | | 197/197 (100 %) | 1 diff (99.5 %id) |
CR603339 | Placenta Cot 25-normalized | CCDC91.c | 529 to 2071 | 1 to 1543 | | tiling clone, | | 1543/1543 (100 %) | 0 diff (100 %id) |
AL544393 | placenta, Placenta Cot 25-normalized | CCDC91.c | 529 to 1250 | 1 to 717 | | | | 717/721 (99 %) | 6 diff (99.2 %id) |
BJ991297 | hepatoblastoma | CCDC91.c | 2151 to 2690 | 540 to 1 | | tiling clone, | | 540/540 (100 %) | 0 diff (100 %id) |
BG722964 | testis | CCDC91.d | 1 to 677 | 1 to 678 | | | | 678/751 (90 %) | 10 diff (98.7 %id) |
BC028682 | testis | CCDC91.d | 6 to 1441 | 1 to 1436 | V284M | tiling clone, available from MGC, AAA | Possibly primed on the genome, locally A rich (19/20 A in genome downstream of last aligned base) | 1436/1436 (100 %) | 4 diff (99.8 %id) |
AK093152 | testis | CCDC91.e | 1 to 1626 | 2 to 1627 | V284M | tiling clone, available from FLJ, | | 1627/1627 (100 %) | 4 diff (99.8 %id) |
AX747957 | | CCDC91.e | 1 to 1626 | 2 to 1627 | V284M | | | 1627/1627 (100 %) | 4 diff (99.8 %id) |
DB024902 | testis | CCDC91.e | 1 to 552 | 2 to 553 | | capped | | 552/552 (100 %) | 1 diff (99.9 %id) |
TI_1948093866 | | CCDC91.e | 364 to 1044 | 120 to 801 | | tiling clone, | | 682/1261 (54 %) | 10 diff (99.3 %id) |
CV024275 | mixed | CCDC91.e | 373 to 981 | 1 to 609 | | | | 609/614 (99 %) | 1 diff (99.9 %id) |
TI_1948093703 | | CCDC91.e | 390 to 1039 | 133 to 786 | | | | 652/1271 (51 %) | 17 diff (98.7 %id) |
TI_1948094034 | | CCDC91.e | 396 to 862 | 122 to 582 | | | | 461/1205 (38 %) | 10 diff (99.2 %id) |
AW977447 | | CCDC91.e | 449 to 1092 | 645 to 1 | | | Submitted on the opposite strand | 645/645 (100 %) | 10 diff (98.5 %id) |
DB175825 | kidney, tumor tissue | CCDC91.e | 482 to 1044 | 2 to 564 | | capped | | 563/566 (99 %) | 2 diff (99.7 %id) |
BE813898 | breast_normal | CCDC91.e | 488 to 1065 | 1 to 579 | | | | 579/579 (100 %) | 8 diff (98.7 %id) |
DB208931 | trachea | CCDC91.e | 502 to 965 | 2 to 465 | | capped | | 464/464 (100 %) | 6 diff (98.8 %id) |
CR998014 | T-Lymphocytes | CCDC91.e | 504 to 1393 | 1 to 887 | | | | 887/916 (96 %) | 16 diff (98.3 %id) |
CA309037 | Alveolar Macrophage, lung | CCDC91.e | 539 to 1255 | 733 to 16 | | AAA | | 718/718 (100 %) | 2 diff (99.8 %id) |
EL593432 | epidermis, skin | CCDC91.e | 548 to 1044 | 26 to 522 | | | | 497/681 (72 %) | 5 diff (99.3 %id) |
DA039055 | bladder | CCDC91.e | 560 to 1118 | 2 to 560 | | capped | | 559/560 (99 %) | 1 diff (99.9 %id) |
BQ434941 | leiomyosarcoma, uterus | CCDC91.e | 570 to 1353 | 1 to 794 | | | | 794/925 (85 %) | 24 diff (97.5 %id) |
BQ429141 | testis | CCDC91.e | 580 to 1245 | 1 to 670 | | | | 668/707 (94 %) | 9 diff (98.8 %id) |
BE550091 | carcinoid, lung | CCDC91.e | 593 to 1141 | 1 to 549 | | | Submitted on the opposite strand | 549/549 (100 %) | 0 diff (100 %id) |
BP291677 | lung | CCDC91.e | 600 to 1044 | 1 to 445 | | | | 445/577 (77 %) | 1 diff (99.9 %id) |
AA767888 | germinal center B cell | CCDC91.e | 625 to 1099 | 478 to 4 | | | | 475/478 (99 %) | 0 diff (100 %id) |
AI271949 | Kidney | CCDC91.e | 636 to 1088 | 453 to 1 | | | | 453/453 (100 %) | 0 diff (100 %id) |
BM013483 | breast, mammary adenocarcinoma, cell line | CCDC91.e | 651 to 1044 | 14 to 407 | | AAA | | 394/615 (64 %) | 7 diff (98.9 %id) |
TI_59391378 | | CCDC91.e | 651 to 1044 | 126 to 519 | | | | 394/708 (55 %) | 7 diff (99.1 %id) |
AW819648 | stomach | CCDC91.e | 703 to 1247 | 16 to 560 | | | | 545/560 (97 %) | 21 diff (96.3 %id) |
AV716641 | | CCDC91.e | 713 to 1449 | 1 to 737 | | | | 737/737 (100 %) | 2 diff (99.8 %id) |
AI679779 | poorly differentiated adenocarcinoma withsignet ring cell features, stomach | CCDC91.e | 762 to 1249 | 498 to 11 | | AAA | | 488/488 (100 %) | 2 diff (99.6 %id) |
AI818870 | lung, squamous cell carcinoma, poorlydifferentiated (4 pooled tumors, including primary andmetastatic) | CCDC91.e | 822 to 1242 | 421 to 1 | | | | 421/421 (100 %) | 3 diff (99.3 %id) |
AI266103 | mixed (see below), Pooled human melanocyte, fetal heart, andpregnant uterus | CCDC91.e | 825 to 1249 | 425 to 1 | | | | 425/425 (100 %) | 1 diff (99.8 %id) |
AI802778 | colon, colonic mucosa from 5 ulcerative colitispatients | CCDC91.e | 855 to 1251 | 403 to 7 | | | | 397/403 (98 %) | 0 diff (100 %id) |
BQ429354 | testis | CCDC91.e | 897 to 1383 | 1 to 487 | | tiling clone, | | 487/762 (63 %) | 2 diff (99.8 %id) |
AA612937 | colon, colon tumor RER+ | CCDC91.e | 910 to 1249 | 340 to 1 | | | | 340/340 (100 %) | 1 diff (99.8 %id) |
BP259389 | heart | CCDC91.e | 984 to 1495 | 1 to 512 | | | | 512/569 (89 %) | 6 diff (99.0 %id) |
AI267582 | brain, frontal lobe (see description) | CCDC91.e | 987 to 1332 | 380 to 35 | | AAA | Internal priming: the 3' end of the oligo dT primed clone lies in the CDS | 346/383 (90 %) | 0 diff (100 %id) |
AW367322 | head_neck | CCDC91.e | 991 to 1196 | 13 to 220 | | | | 208/220 (94 %) | 16 diff (92.8 %id) |
AW367252 | head_neck | CCDC91.e | 996 to 1497 | 1 to 502 | | tiling clone, | | 502/555 (90 %) | 3 diff (99.5 %id) |
BQ378966 | uterus_tumor | CCDC91.e | 1030 to 1373 | 344 to 8 | | | | 337/349 (96 %) | 1 diff (99.8 %id) |
BE048618 | Kidney | CCDC91.e | 1043 to 1254 | 214 to 3 | | | | 212/518 (40 %) | 0 diff (100 %id) |
BF988055 | placenta_normal | CCDC91.e | 1044 to 1437 | 405 to 12 | | | | 394/405 (97 %) | 2 diff (99.6 %id) |
DA378054 | thalamus | CCDC91.e | 1044 to 1442 | 151 to 549 | | capped | | 399/548 (72 %) | 8 diff (98.6 %id) |
DB336411 | testis | CCDC91.e | 1091 to 1626 | 536 to 1 | | | | 536/536 (100 %) | 2 diff (99.7 %id) |
BM545687 | ovary (pool of 3) | CCDC91.f | -10 to 734 | 135 to 888 | | tiling clone, | | 754/1154 (65 %) | 30 diff (97.5 %id) |
CR749586 | Liver | CCDC91.f | 581 to 2470 | 1 to 1890 | | tiling clone, available from DKFZ, AAA | Possibly primed on the genome, locally A rich (19/20 A in genome downstream of last aligned base) | 1890/1892 (99 %) | 5 diff (99.8 %id) |
AK309181 | thalamus | CCDC91.g | 1 to 1666 | 2 to 1667 | G7C S93T | tiling clone, | | 1667/1667 (100 %) | 4 diff (99.8 %id) |
DA386101 | thalamus | CCDC91.g | 1 to 572 | 2 to 572 | | capped | | 571/571 (100 %) | 3 diff (99.5 %id) |
BI086262 | cervix | CCDC91.h | 1 to 679 | 1 to 685 | | tiling clone, | | 685/943 (72 %) | 19 diff (98.0 %id) |
DB181661 | liver, tumor tissue | CCDC91.h | 14 to 574 | 2 to 562 | | capped | | 561/561 (100 %) | 0 diff (100 %id) |
CV575034 | cornea, eye | CCDC91.h | 17 to 657 | 1 to 641 | | tiling clone, | | 641/641 (100 %) | 0 diff (100 %id) |
DA346049 | substantia nigra | CCDC91.h | 51 to 640 | 2 to 592 | | capped | | 591/591 (100 %) | 1 diff (99.9 %id) |
EB387108 | eye, optic nerve | CCDC91.h | 584 to 1453 | 1 to 870 | | tiling clone, | | 870/870 (100 %) | 2 diff (99.8 %id) |
BI460249 | testis | CCDC91.i | 1 to 607 | 7 to 613 | | tiling clone, | | 613/613 (100 %) | 5 diff (99.2 %id) |
BI560715 | testis | CCDC91.i | 1 to 629 | 7 to 635 | | | | 635/635 (100 %) | 5 diff (99.3 %id) |
DB033252 | testis | CCDC91.i | 1 to 567 | 5 to 572 | | capped | | 571/571 (100 %) | 3 diff (99.5 %id) |
DB038409 | testis | CCDC91.i | 1 to 565 | 5 to 571 | | capped | | 570/570 (100 %) | 3 diff (99.5 %id) |
DB045971 | testis | CCDC91.i | 1 to 564 | 5 to 568 | | capped | | 567/567 (100 %) | 1 diff (99.9 %id) |
DB047356 | testis | CCDC91.i | 1 to 543 | 5 to 548 | | capped | | 547/547 (100 %) | 4 diff (99.3 %id) |
DB450209 | testis | CCDC91.i | 1 to 444 | 3 to 446 | | | | 446/446 (100 %) | 3 diff (99.4 %id) |
TI_44349705 | | CCDC91.i | 1 to 629 | 92 to 720 | | | | 630/720 (87 %) | 7 diff (99.1 %id) |
DB031231 | testis | CCDC91.i | 1 to 603 | 2 to 606 | | capped | | 605/605 (100 %) | 3 diff (99.6 %id) |
DB058995 | testis | CCDC91.i | 1 to 518 | 2 to 520 | | capped | | 519/519 (100 %) | 4 diff (99.3 %id) |
BI828846 | brain, medulla | CCDC91.i | 12 to 740 | 1 to 727 | L132* | tiling clone, | | 727/884 (82 %) | 15 diff (98.4 %id) |
TI_57172659 | | CCDC91.i | 12 to 740 | 34 to 760 | L132* | | | 727/917 (79 %) | 16 diff (98.3 %id) |
BC035168 | testis | CCDC91.j-u | 1 to 3132 | 1 to 3133 | exact | tiling clone, available from MGC, AAA | Possibly primed on the genome, locally A rich (19/20 A in genome downstream of last aligned base) | 3133/3133 (100 %) | 10 diff (99.7 %id) |
FN160278 | breast carcinoma | CCDC91.j-u | 1995 to 2118 | 124 to 1 | | | Submitted on the opposite strand | 124/124 (100 %) | 2 diff (98.4 %id) |
BI464145 | testis | CCDC91.k | 1 to 707 | 7 to 711 | S91P L95F Q96S Q97K I99F ... | tiling clone, | | 711/723 (98 %) | 18 diff (97.6 %id) |
DB442883 | testis | CCDC91.k | 1 to 444 | 5 to 449 | | | | 449/449 (100 %) | 3 diff (99.4 %id) |
DB460812 | testis | CCDC91.k | 1 to 382 | 5 to 386 | | | | 386/386 (100 %) | 1 diff (99.8 %id) |
DB257984 | uterus | CCDC91.l | 1 to 573 | 2 to 574 | L37X | tiling clone, capped | | 573/573 (100 %) | 2 diff (99.7 %id) |
AA910761 | pooled | CCDC91.m | 1 to 380 | 384 to 5 | V13M | tiling clone, | | 380/384 (98 %) | 1 diff (99.8 %id) |
AW468671 | pooled | CCDC91.m | 3 to 380 | 383 to 6 | | | | 378/383 (98 %) | 2 diff (99.5 %id) |
DA352005 | substantia nigra | CCDC91.n | 1 to 552 | 2 to 554 | exact | tiling clone, capped | | 553/553 (100 %) | 2 diff (99.7 %id) |
DA374359 | thalamus | CCDC91.o | 1 to 474 | 2 to 475 | exact | tiling clone, capped | | 474/474 (100 %) | 1 diff (99.8 %id) |
BX484673 | | CCDC91.p | 1 to 700 | 5 to 704 | exact | tiling clone, | | 704/704 (100 %) | 5 diff (99.3 %id) |
AI700920 | Kidney | CCDC91.q | 1 to 237 | 237 to 1 | exact | tiling clone, | | 237/237 (100 %) | 0 diff (100 %id) |
AK092571 | Prostate | CCDC91.r-u | 1 to 2173 | 2 to 2173 | exact | tiling clone, available from FLJ, | | 2173/2173 (100 %) | 6 diff (99.8 %id) |
DA868388 | Prostate | CCDC91.r-u | 1 to 573 | 2 to 574 | | capped | | 573/573 (100 %) | 1 diff (99.9 %id) |
H69958.
matches multiple genes | nose, olfactory epithelium | CCDC91.r-u | 552 to 935 | 387 to 1 | | tiling clone, | also hits gene yameri | 387/387 (100 %) | 4 diff (99.0 %id) |
DB329766 | Prostate | CCDC91.r-u | 1644 to 2173 | 529 to 1 | | | | 529/529 (100 %) | 2 diff (99.7 %id) |
DA756289 | | CCDC91.s | 1 to 501 | 2 to 502 | | tiling clone, to resequence, capped | | 501/501 (100 %) | 0 diff (100 %id) |
N22663 | | CCDC91.s | 378 to 683 | 1 to 306 | | tiling clone, | | 306/307 (99 %) | 1 diff (99.7 %id) |
DB325211 | | CCDC91.s | 1442 to 1979 | 540 to 1 | exact | tiling clone, to resequence, | | 540/540 (100 %) | 2 diff (99.7 %id) |
BQ932577 | sciatic nerve | CCDC91.t-u | 1 to 876 | 1 to 876 | F2Y K4R I5T K6E Q7K ... | tiling clone, | | 876/877 (99 %) | 6 diff (99.4 %id) |
AV703807 | adrenal gland | CCDC91.t-u | 8 to 410 | 16 to 417 | | tiling clone, | | 402/417 (96 %) | 6 diff (98.6 %id) |
BF208203 | bladder, carcinoma, cell line | CCDC91.t-u | 63 to 779 | 1 to 721 | | | | 721/902 (79 %) | 45 diff (95.1 %id) |
BF208261 | bladder, carcinoma, cell line | CCDC91.t-u | 63 to 623 | 1 to 555 | | | | 555/555 (100 %) | 30 diff (94.6 %id) |
AL570537 | placenta, Placenta Cot 25-normalized | CCDC91.t-u | 69 to 1068 | 995 to 1 | | | | 995/1022 (97 %) | 14 diff (98.7 %id) |
BE564279 | bladder, carcinoma, cell line | CCDC91.t-u | 83 to 768 | 1 to 680 | | | | 680/682 (99 %) | 25 diff (96.4 %id) |
BE564650 | bladder, carcinoma, cell line | CCDC91.t-u | 83 to 779 | 1 to 701 | | | | 701/735 (95 %) | 16 diff (97.9 %id) |
BE564933 | bladder, carcinoma, cell line | CCDC91.t-u | 83 to 655 | 1 to 573 | | | | 573/879 (65 %) | 16 diff (98.2 %id) |
BE564847 | bladder, carcinoma, cell line | CCDC91.t-u | 83 to 617 | 1 to 529 | | | | 529/855 (61 %) | 12 diff (98.6 %id) |
BE564425 | bladder, carcinoma, cell line | CCDC91.t-u | 83 to 724 | 1 to 627 | | | | 627/880 (71 %) | 25 diff (97.2 %id) |
BE565436 | bladder, carcinoma, cell line | CCDC91.t-u | 83 to 754 | 1 to 665 | | | | 665/800 (83 %) | 22 diff (97.3 %id) |
BE564952 | bladder, carcinoma, cell line | CCDC91.t-u | 83 to 724 | 1 to 635 | | | | 635/870 (72 %) | 21 diff (97.6 %id) |
BF791317 | muscle (skeletal) | CCDC91.t-u | 206 to 931 | 1 to 710 | | | | 710/885 (80 %) | 22 diff (97.6 %id) |
BE176109 | head_neck | CCDC91.t-u | 250 to 425 | 174 to 1 | | | Submitted on the opposite strand | 174/185 (94 %) | 3 diff (98.4 %id) |
BE176068 | head_neck | CCDC91.t-u | 264 to 447 | 13 to 195 | | | | 183/200 (91 %) | 9 diff (95.5 %id) |
BM472102 | melanotic melanoma, skin | CCDC91.t-u | 317 to 1112 | 9 to 814 | | | | 806/1005 (80 %) | 21 diff (98.0 %id) |
BF921132 | nervous_tumor | CCDC91.t-u | 340 to 764 | 110 to 534 | | | | 425/534 (79 %) | 6 diff (98.9 %id) |
TI_149287526 | | CCDC91.t-u | 347 to 1126 | 860 to 76 | | AAA | Possibly primed on the genome, locally A rich (19/20 A in genome downstream of last aligned base) | 785/1155 (67 %) | 19 diff (98.4 %id) |
FN169078 | breast carcinoma | CCDC91.t-u | 369 to 481 | 113 to 1 | | | Submitted on the opposite strand | 113/113 (100 %) | 0 diff (100 %id) |
FN135639 | breast carcinoma | CCDC91.t-u | 389 to 456 | 67 to 1 | | | Submitted on the opposite strand | 67/68 (98 %) | 1 diff (98.6 %id) |
BG617063 | Liver | CCDC91.t-u | 399 to 1074 | 1 to 672 | | | | 672/672 (100 %) | 4 diff (99.5 %id) |
TI_154132967 | | CCDC91.t-u | 430 to 1126 | 789 to 97 | | AAA | Possibly primed on the genome, locally A rich (19/20 A in genome downstream of last aligned base) | 693/809 (85 %) | 9 diff (98.9 %id) |
BM972834 | lung | CCDC91.t-u | 545 to 1126 | 601 to 19 | | AAA | Possibly primed on the genome, locally A rich (19/20 A in genome downstream of last aligned base) | 583/583 (100 %) | 1 diff (99.9 %id) |
FN048720 | breast carcinoma | CCDC91.t-u | 583 to 685 | 1 to 103 | | | | 103/104 (99 %) | 1 diff (99.1 %id) |
AI744609 | pooled | CCDC91.t-u | 597 to 1120 | 552 to 29 | | AAA | Possibly primed on the genome, locally A rich (19/20 A in genome downstream of last aligned base) | 524/524 (100 %) | 3 diff (99.5 %id) |
BF743681 | breast | CCDC91.t-u | 607 to 963 | 1 to 356 | | | | 356/364 (97 %) | 7 diff (98.1 %id) |
CB163505 | Liver | CCDC91.t-u | 613 to 1127 | 532 to 18 | | tiling clone, | Submitted on the opposite strand | 515/532 (96 %) | 0 diff (100 %id) |
CB163514 | Liver | CCDC91.t-u | 613 to 1127 | 532 to 18 | | | Submitted on the opposite strand | 515/532 (96 %) | 0 diff (100 %id) |
BF743678 | breast | CCDC91.t-u | 614 to 963 | 1 to 347 | | | | 347/355 (97 %) | 12 diff (96.7 %id) |
AA863032 | 2 pooled tumors (clear cell type), Kidney | CCDC91.t-u | 621 to 1127 | 511 to 5 | | | | 507/511 (99 %) | 0 diff (100 %id) |
BF082734 | breast | CCDC91.t-u | 622 to 963 | 1 to 342 | | | | 342/350 (97 %) | 11 diff (96.9 %id) |
FN121802 | breast carcinoma | CCDC91.t-u | 641 to 720 | 1 to 82 | | | | 82/82 (100 %) | 5 diff (94.0 %id) |
BF109606 | pooled | CCDC91.t-u | 643 to 1126 | 494 to 11 | | AAA | Possibly primed on the genome, locally A rich (19/20 A in genome downstream of last aligned base) | 484/484 (100 %) | 1 diff (99.8 %id) |
BE221484 | malignant melanoma, metastatic to lymphnode, skin | CCDC91.t-u | 670 to 1126 | 483 to 27 | | AAA | Possibly primed on the genome, locally A rich (19/20 A in genome downstream of last aligned base) | 457/457 (100 %) | 0 diff (100 %id) |
AA970322 | 2 pooled tumors (clear cell type), Kidney | CCDC91.t-u | 673 to 1127 | 459 to 5 | | | | 455/459 (99 %) | 0 diff (100 %id) |
EH336619 | | CCDC91.t-u | 676 to 757 | 1 to 84 | | | | 84/84 (100 %) | 2 diff (97.7 %id) |
D61905 | | CCDC91.t-u | 680 to 991 | 1 to 312 | | | | 312/312 (100 %) | 0 diff (100 %id) |
DB566756 | hypothalamus | CCDC91.t-u | 684 to 1126 | 1 to 443 | | AAA | Submitted on the opposite strand | 443/443 (100 %) | 1 diff (99.8 %id) |
BF058503 | fibrotheoma, ovary | CCDC91.t-u | 687 to 1126 | 440 to 1 | | | | 440/440 (100 %) | 0 diff (100 %id) |
AA805624 | germinal center B cell | CCDC91.t-u | 691 to 1126 | 446 to 11 | | AAA | Possibly primed on the genome, locally A rich (19/20 A in genome downstream of last aligned base) | 436/436 (100 %) | 0 diff (100 %id) |
AW275229 | brain, three pooled meningiomas | CCDC91.t-u | 696 to 1126 | 431 to 1 | | | | 431/431 (100 %) | 0 diff (100 %id) |
AW275205 | lung, two pooled squamous cell carcinomas | CCDC91.t-u | 706 to 1126 | 421 to 1 | | | | 421/421 (100 %) | 1 diff (99.8 %id) |
AA813929 | germinal center B cell | CCDC91.t-u | 716 to 1127 | 414 to 3 | | | | 412/414 (99 %) | 0 diff (100 %id) |
CA444104 | Fibrosarcoma | CCDC91.t-u | 716 to 1126 | 430 to 19 | | AAA | Possibly primed on the genome, locally A rich (19/20 A in genome downstream of last aligned base) | 412/412 (100 %) | 1 diff (99.8 %id) |
AA857222 | adenocarcinoma, colon | CCDC91.t-u | 719 to 1127 | 411 to 3 | | | | 409/411 (99 %) | 0 diff (100 %id) |
FN171064 | breast carcinoma | CCDC91.t-u | 721 to 834 | 114 to 1 | | | Submitted on the opposite strand | 114/114 (100 %) | 3 diff (97.4 %id) |
AA648864 | germinal center B cell | CCDC91.t-u | 723 to 984 | 262 to 1 | | | | 262/262 (100 %) | 1 diff (99.7 %id) |
AA742248 | germinal center B cell | CCDC91.t-u | 730 to 1127 | 409 to 12 | | | | 398/409 (97 %) | 0 diff (100 %id) |
AI802999 | pooled | CCDC91.t-u | 732 to 1126 | 424 to 30 | | AAA | Possibly primed on the genome, locally A rich (19/20 A in genome downstream of last aligned base) | 395/395 (100 %) | 0 diff (100 %id) |
AA749018 | germinal center B cell | CCDC91.t-u | 742 to 1126 | 396 to 12 | | AAA | Possibly primed on the genome, locally A rich (19/20 A in genome downstream of last aligned base) | 385/385 (100 %) | 0 diff (100 %id) |
FN062687 | breast carcinoma | CCDC91.t-u | 762 to 867 | 1 to 106 | | | | 106/111 (95 %) | 4 diff (96.4 %id) |
AI186645 | placenta | CCDC91.t-u | 762 to 1126 | 375 to 11 | | AAA | Possibly primed on the genome, locally A rich (19/20 A in genome downstream of last aligned base) | 365/365 (100 %) | 1 diff (99.8 %id) |
AW275212 | lung, two pooled squamous cell carcinomas | CCDC91.t-u | 762 to 1126 | 365 to 1 | | | | 365/365 (100 %) | 0 diff (100 %id) |
AW970619 | | CCDC91.t-u | 786 to 1127 | 480 to 138 | | | Submitted on the opposite strand | 343/480 (71 %) | 0 diff (100 %id) |
FN077545 | breast carcinoma | CCDC91.t-u | 788 to 867 | 87 to 6 | | | Submitted on the opposite strand | 82/88 (93 %) | 0 diff (100 %id) |
AW275236 | brain, three pooled meningiomas | CCDC91.t-u | 789 to 1126 | 338 to 1 | | | | 338/338 (100 %) | 0 diff (100 %id) |
BU954463 | mixed (pool of 40 RNAs) | CCDC91.t-u | 806 to 1125 | 1 to 320 | | | | 320/356 (89 %) | 3 diff (99.2 %id) |
N66890 | cochlea, ear | CCDC91.t-u | 843 to 1127 | 294 to 4 | | | | 291/295 (98 %) | 0 diff (100 %id) |
AA721285 | germinal center B cell | CCDC91.t-u | 893 to 1126 | 246 to 13 | | AAA | Possibly primed on the genome, locally A rich (19/20 A in genome downstream of last aligned base) | 234/234 (100 %) | 0 diff (100 %id) |
AA502674 | ovary | CCDC91.t-u | 900 to 1127 | 248 to 21 | | | | 228/248 (91 %) | 0 diff (100 %id) |
BE182837 | head_neck | CCDC91.t-u | 950 to 1059 | 1 to 109 | | | | 109/109 (100 %) | 5 diff (95.5 %id) |
AI431503 | lymph node, lymphoma, follicular mixed small and largecell | CCDC91.t-u | 957 to 1126 | 170 to 1 | | | | 170/188 (90 %) | 2 diff (99.0 %id) |
BG530183 | embryonal carcinoma, testis | CCDC91.u-u | 1 to 777 | 1 to 782 | exact | tiling clone, | | 782/798 (97 %) | 42 diff (94.8 %id) |
CR744446 | | CCDC91.u-u | 307 to 893 | 1 to 588 | | tiling clone, | | 588/588 (100 %) | 2 diff (99.7 %id) |
AW139264 | | CCDC91.u-u | 783 to 1072 | 307 to 18 | | tiling clone, AAA | Possibly primed on the genome, locally A rich (19/20 A in genome downstream of last aligned base) | 290/290 (100 %) | 0 diff (100 %id) |
BI913840 | brain | CCDC91.va | 1 to 522 | 1 to 534 | S2T T12I P17S L24S G25W ... | tiling clone, | | 534/895 (59 %) | 17 diff (98.2 %id) |
BI914972 | brain | CCDC91.va | 1 to 512 | 1 to 517 | S53A G54E E55S R56E E57R ... | tiling clone, | | 517/1026 (50 %) | 12 diff (98.9 %id) |
TI_57243400 | | CCDC91.va | 1 to 522 | 28 to 561 | S2T T12I P17S L24S G25W ... | | | 534/922 (57 %) | 15 diff (98.4 %id) |
TI_57243625 | | CCDC91.va | 1 to 512 | 30 to 546 | S53A G54E E55S R56E E57R ... | AAA | | 517/1038 (49 %) | 20 diff (98.1 %id) |
BG219692 | | CCDC91.va | 184 to 486 | 1 to 303 | | AAA | Possibly primed on the genome, locally A rich (22/22 A in genome downstream of last aligned base) | 303/303 (100 %) | 0 diff (100 %id) |
BG181700 | | CCDC91.va | 207 to 490 | 1 to 285 | | | | 285/285 (100 %) | 2 diff (99.3 %id) |
BG219999 | | CCDC91.va | 257 to 808 | 564 to 14 | | tiling clone, | Submitted on the opposite strand | 551/828 (66 %) | 19 diff (97.8 %id) |
CV800522 | Blastocyst, pluripotent cell line derived fromblastocyst inner cell mass | CCDC91.vb | 1 to 637 | 43 to 675 | exact | tiling clone, | | 635/846 (75 %) | 11 diff (98.7 %id) |
BX472549 | | CCDC91.vb | 444 to 793 | 1 to 351 | | tiling clone, | | 351/351 (100 %) | 3 diff (99.2 %id) |
BG201290 | | CCDC91.vc | 1 to 724 | 3 to 717 | L23F C34W Q35P S37V D51N ... | tiling clone, AAA | | 717/726 (98 %) | 32 diff (95.6 %id) |
BG189509 | | CCDC91.vc | 2 to 735 | 7 to 739 | P2L V32G V57X Y58N F64V | tiling clone, AAA | Possibly primed on the genome, locally A rich (19/20 A in genome downstream of last aligned base) | 733/740 (99 %) | 17 diff (97.8 %id) |
DA714104 | | CCDC91.vd | 1 to 570 | 2 to 571 | E8K E16S Q17K | tiling clone, capped | | 570/570 (100 %) | 3 diff (99.5 %id) |
D61459 | | CCDC91.ve-u | 1 to 331 | 1 to 330 | R2K K3E E50X | tiling clone, | | 330/330 (100 %) | 4 diff (98.8 %id) |
BF364153 | nervous_normal | CCDC91.ve-u | 2 to 519 | 522 to 5 | K3N K4I K10R I19X | tiling clone, | | 518/523 (99 %) | 0 diff (100 %id) |
BF364072 | nervous_normal | CCDC91.ve-u | 131 to 498 | 381 to 10 | | tiling clone, | | 372/381 (97 %) | 0 diff (100 %id) |
DB495701 | hypothalamus | CCDC91.vf | 1 to 506 | 2 to 507 | exact | tiling clone, | | 507/507 (100 %) | 1 diff (99.9 %id) |
BG205560 | | CCDC91.vg | 1 to 273 | 278 to -2 | exact | tiling clone, | Submitted on the opposite strand | 278/281 (98 %) | 4 diff (98.6 %id) |
BG193195 | | CCDC91.vg | 1 to 256 | 1 to 256 | C35F | tiling clone, AAA | Possibly primed on the genome, locally A rich (22/22 A in genome downstream of last aligned base) | 256/256 (100 %) | 2 diff (99.3 %id) |
BG216179 | | CCDC91.vg | 1 to 274 | 274 to 1 | exact | | Submitted on the opposite strand | 274/274 (100 %) | 7 diff (97.5 %id) |
BG204391 | | CCDC91.vh | 1 to 170 | 3 to 171 | | tiling clone, | | 171/171 (100 %) | 3 diff (98.3 %id) |
BG202314 | | CCDC91.vh | 9 to 177 | 1 to 169 | | tiling clone, | | 169/169 (100 %) | 8 diff (95.3 %id) |
BG190053 | | CCDC91.vh | 10 to 170 | 1 to 160 | | | | 160/160 (100 %) | 6 diff (96.3 %id) |
DB302128 | amygdala | Gene CCDC91, variant not shown | | | | | This clone was ignored | | |
DA160530 | amygdala | Gene CCDC91, variant not shown | | | | capped | This clone was ignored | | |
BM718972 | eye, fetal eye | Gene CCDC91, variant not shown | | | | | Suspected internal deletion, this clone was ignored | | |
? | Gene Summary |
Gene on genome |
mRNA:.a, .b, .c, .d, .e, .f, .g, .h, .i, .j-u, .k, .l, .m, .n, .o, .p, .q, .r-u, .s, .t-u, .u-u, .va, .vb, .vc, .vd, .ve-u, .vf, .vg, .vh |
Alternative mRNAs features, proteins, introns, exons, sequences |
Expression Tissue |
Function, regulation, related genes CI |
To mine knowledge about the gene, please click the 'Gene Summary' or the 'Function, regulation, related genes ' tab at the top of the page. The 'Gene Summary' page includes all we learnt about the gene, functional annotations of neighboring genes, maps, links to other sites and the bibliography. The 'Function, regulation, related genes ' page includes Diseases (D), Pathways, GO annotations, conserved domains (C), interactions (I) reference into function, and pointers to all genes with the same functional annotation.
To compare alternative variants, their summarized annotations, predicted proteins, introns and exons, or to access any sequence, click the 'Alternative mRNAs features' tab. To see a specific mRNA variant diagram, sequence and annotation, click the variant name in the 'mRNA' tab. To examine expression data from all cDNAs clustered in this gene by AceView, click the 'Expression tissue'.
If you know more about this gene, or found errors, please share your knowledge. Thank you !